Lung cancer gene map after drug failure could guide next steps
NCT ID NCT05219162
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This completed study looked at gene changes in 182 people with advanced lung cancer whose disease got worse after first-line treatment with Osimertinib. Researchers collected tissue and blood samples to understand why the drug stopped working. The goal is to use this information to help choose better treatments for these patients in the future.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could help doctors choose better second-line treatments for lung cancer patients whose disease progresses after Osimertinib.
What could go wrong
This is an observational study, not a treatment trial. It may not directly improve outcomes, and results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED NSCLC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Beijing, 100210, China
-
Research Site
Changsha, 410013, China
-
Research Site
Chengdu, 610014, China
-
Research Site
Dalian, 116023, China
-
Research Site
Foshan, 528000, China
-
Research Site
Fuzhou, 350014, China
-
Research Site
Harbin, 150081, China
-
Research Site
Hefei, 230001, China
-
Research Site
Hefei, 230601, China
-
Research Site
Linhai, 317000, China
-
Research Site
Luoyang, 471003, China
-
Research Site
Rizhao, 276826, China
-
Research Site
Shanghai, 200032, China
-
Research Site
Taizhou, 225300, China
-
Research Site
Tianjin, 300060, China
-
Research Site
Zhengzhou, 450000, China